ascopubs.org4d
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...
pharmaphorum3d
Pharma M&A rumour mill grinds out Mirati's name again
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).
pharmaphorum3d
BMS gets FDA approval for Krazati in colorectal cancer
BMS claimed rights to Krazati when it acquired Mirati Therapeutics last year in a $5.8 billion deal. So far, neither of the KRAS drugs have lived up to their initial sales expectations ...
Yahoo Finance2d
Edgewise Therapeutics, Inc. (EWTX)
After hours: February 13 at 5:32:04 PM EST Loading Chart for EWTX ...
Yahoo Finance1d
CytoMed Therapeutics Limited (GDTC)
After hours: February 10 at 5:00:28 PM EST Loading Chart for GDTC ...
MarketWatch5d
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc.-5.60% $1.56B ...